Scynexis Inc SCYX
We take great care to ensure that the data presented and summarized in this overview for SCYNEXIS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SCYX
View all-
Federated Hermes, Inc. Pittsburgh, PA2.9MShares$2.11 Million0.01% of portfolio
-
Kingdon Capital Management, L.L.C. New York, NY2.24MShares$1.63 Million0.24% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.66MShares$1.21 Million0.0% of portfolio
-
Avidity Partners Management LP Dallas, TX1.23MShares$897,1040.26% of portfolio
-
Amh Equity LTD627KShares$457,7370.97% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC556KShares$405,5550.7% of portfolio
-
Acadian Asset Management LLC Boston, MA443KShares$323,4350.0% of portfolio
-
Black Rock Inc. New York, NY424KShares$309,3280.0% of portfolio
-
Geode Capital Management, LLC Boston, MA419KShares$306,2260.0% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX353KShares$258,0480.01% of portfolio
Latest Institutional Activity in SCYX
Top Purchases
Top Sells
About SCYX
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Insider Transactions at SCYX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 09
2025
|
Gonzalez David Angulo Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,000
+2.74%
|
$0
$0.84 P/Share
|
|
Mar 20
2025
|
Gonzalez David Angulo Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,800
+1.71%
|
$13,800
$1.05 P/Share
|
|
Mar 19
2025
|
Gonzalez David Angulo Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+0.64%
|
$5,000
$1.07 P/Share
|
|
Jan 23
2025
|
Scott Sukenick Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
92,511
+17.48%
|
-
|
|
Jan 23
2025
|
Gonzalez David Angulo Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
262,927
+25.43%
|
-
|
|
Jan 23
2025
|
Ivor Macleod Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
92,511
+26.19%
|
-
|
|
Sep 12
2024
|
Gonzalez David Angulo Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+3.79%
|
$20,000
$1.37 P/Share
|
|
Jun 20
2024
|
David C Hastings |
BUY
Grant, award, or other acquisition
|
Direct |
23,000
+33.25%
|
-
|
|
Jun 20
2024
|
Guy Macdonald |
BUY
Grant, award, or other acquisition
|
Direct |
23,000
+29.49%
|
-
|
|
Jun 20
2024
|
Brian Philippe Tinmouth |
BUY
Grant, award, or other acquisition
|
Direct |
23,000
+31.08%
|
-
|
|
Jun 20
2024
|
Steven C Gilman |
BUY
Grant, award, or other acquisition
|
Direct |
23,000
+32.86%
|
-
|
|
Jun 20
2024
|
Ann Hanham |
BUY
Grant, award, or other acquisition
|
Direct |
23,000
+33.04%
|
-
|
|
Jun 20
2024
|
Armando Anido |
BUY
Grant, award, or other acquisition
|
Direct |
23,000
+32.39%
|
-
|
|
Feb 16
2024
|
Scott Sukenick Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
15,179
-4.32%
|
$15,179
$1.63 P/Share
|
|
Jan 26
2024
|
Scott Sukenick Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
143,675
+29.02%
|
-
|
|
Jan 26
2024
|
Ivor Macleod Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
143,675
+47.28%
|
-
|
|
Jan 26
2024
|
Gonzalez David Angulo Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
290,590
+37.72%
|
-
|
|
Jun 15
2023
|
Armando Anido |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+28.57%
|
-
|
|
Jun 15
2023
|
Brian Philippe Tinmouth |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+26.32%
|
-
|
|
Jun 15
2023
|
Ann Hanham |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+29.74%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 628K shares |
|---|---|
| Open market or private purchase | 20K shares |